$CARSGEN-B(02171)$ I reviewed some small-sample data on IQGAP3+ in gastric cancer, about two-thirds of patients exhibit high expression. This suggests roughly a third could significantly benefit, which is quite promising. Having a well-defined biomarker and target population provides a solid foundation for future commercialization. The key now is whether the company can improve cost efficiency and innovate its sales approach to gain an edge.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
